0

NOW ENROLLING: Phase 3 SURPASS-IPF for people with idiopathic pulmonary fibrosis. Click to learn more about our clinical trial.

Skip to Content
Celea Therapeutics
Deupirfenidone
Patients & Physicians
About Us
Careers
News
Contact Us
Celea Therapeutics
Deupirfenidone
Patients & Physicians
About Us
Careers
News
Contact Us
Deupirfenidone
Patients & Physicians
About Us
Careers
News
Contact Us

Consequences of Adverse Events Associated with Antifibrotic Medications... American Thoracic Society International Conference. 2024. Graham CS, et al. [Poster]

Publication
May 20
Written by Christine Mackenzie
Christine Mackenzie
Previous
Previous

Bayesian Approach for ELEVATE IPF: Randomized, Double-blind, Placebo-controlled Trial... CHEST Annual Meeting. 2024. Zhang Y, et al. [Oral Presentation]

Next
Next

A Randomized Phase 1 Evaluation of Deupirfenidone, a Novel Deuterium-Containing Drug Candidate... Clinical Pharmacology in Drug Development. 2022. Chen MC, et al.

Celea Therapeutics

6 Tide Street, Suite 400
Boston, MA 02210


info@celeatx.com

DEUPIRFENIDONE
PATIENTS & PHYSICIANS
ABOUT US
CAREERS
NEWS & PUBLICATIONS
CONTACT

© 2026 Celea Therapeutics, Inc. All rights reserved. Expanded Access Policy

The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether deupirfenidone is safe and effective. No regulatory agency has made any such determination that deupirfenidone is safe or effective for use by the general public for any indication.